The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer

No abstract is available for this paper.

• Publication year

  2007

• Venue

  American journal of hematology/oncology

• Publication date

  2007-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ajh.20985PMID 17636471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma.

  2007cited by this paper
• Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma.

  2007cited by this paper
• Strong association of interleukin-6 -174 G>C promoter polymorphism with increased risk of oral cancer.

  2006cited by this paper
• Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study.

  2006cited by this paper
• Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer.

  2006cited by this paper
• Association of platelet glycoprotein Ia polymorphism with minor increase of risk for oral cancer.

  2006cited by this paper
• TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study

  2005cited by this paper
• Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients

  2005cited by this paper
• Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact

  2005cited by this paper
• Thrombophilia in cancer.

  2005cited by this paper
• Thrombin-activatable fibrinolysis inhibitor.

  2004cited by this paper
• Increased circulating levels of thrombin‐activatable fibrinolysis inhibitor in lung cancer patients

  2004cited by this paper
• Expressions of Matrix Metalloproteinases in Early-Stage Oral Squamous Cell Carcinoma as Predictive Indicators for Tumor Metastases and Prognosis

  2004cited by this paper
• Tumor growth and metastasis are not affected in thrombin‐activatable fibrinolysis inhibitor‐deficient mice

  2004cited by this paper
• Urokinase gene 3′‐UTR T/C polymorphism is associated with oral cancer

  2004cited by this paper
• Risk factors for oral and pharyngeal cancer in young adults.

  2004cited by this paper
• Plasminogen activator inhibitor-1.

  2004cited by this paper
• Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin‐activatable fibrinolysis inhibitor

  2003cited by this paper
• Thrombin‐activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)

  2003cited by this paper
• Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence

  2003cited by this paper
• New functions for the matrix metalloproteinases in cancer progression

  2002cited by this paper
• Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.

  2002cited by this paper
• Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme*

  2002cited by this paper
• The plasminogen activation system in tumor growth, invasion, and metastasis

  2000cited by this paper
• Molecular pathogenesis of oral squamous carcinoma

  2000cited by this paper
• Reduced activity of TAFI (thrombin‐activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia

  2000cited by this paper

• Thrombosis Risk Associated with Head and Neck Cancer: A Review

  2019cites this paper
• Suppression of TAFI by siRNA inhibits invasion and migration of breast cancer cells.

  2017cites this paper
• Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study

  2015cites this paper
• Effect of thrombosis-related gene polymorphisms upon oral cancer: a regression analysis.

  2013cites this paper
• The interplay between hemostasis and malignancy: the oral cancer paradigm.

  2012cites this paper
• An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.

  2011cites this paper
• The Role of Thrombin-Activatable Fibrinolysis Inhibitor in the Pathophysiology of Hemostasis

  2010cites this paper
• High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double‐deficient mice

  2010cites this paper
• The Role of Thrombin-Activatable Fibrinolysis Inhibitor in the Pathophysiology of Hemostasis

  2010cites this paper
• Analysis of a new crystal form of procarboxypeptidase B: further insights into the catalytic mechanism.

  2010cites this paper
• Thrombin activatable fibrinolysis inhibitor (TAFI) in blood of patients with colon and breast cancer

  2010cites this paper
• Association of leptin −2548G/A and leptin receptor Q223R polymorphisms with increased risk for oral cancer

  2009cites this paper
• Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer.

  2009cites this paper
• TAFIa inhibitors in the treatment of thrombosis.

  2008cites this paper
• Review. Animal models of carcinogenesis in the digestive system.

  2007cites this paper
• Heterozygosity for interleukin-18 -607 A/C polymorphism is associated with risk for colorectal cancer.

  2007cites this paper
• Molecular Sciences Thrombosis Risk Associated with Head and Neck Cancer: A Review

  year unknowncites this paper